Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:CI

Cigna Corp. (CI)

295.38
-2.62 (0.88%)
as of Jun 15, 2026, 2:57:28 pm Market Open.
13 watching
0
Investor Insights
star iconJun 15, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Cigna Corp. (CI-N) has received mixed reviews recently, with a focus on its performance following recent policy changes under the Trump administration that have negatively affected health maintenance organizations (HMOs) and pharmacy benefits managers. Experts are highlighting a common theme of compressing margins within the healthcare space. This pessimistic outlook suggests that the current overhang may persist for several more quarters, leading to a cautious approach among investors. The company was noted as a top pick in October 2024, despite a recent decline in stock value. Overall, there are significant concerns surrounding regulatory impacts and their potential effects on profitability.

consensus icon
Consensus
Negative
valuation icon
Valuation
Overvalued
review icon
Similar
UnitedHealth, UNH
PAST TOP PICK
(A Top Pick Oct 29/24, Down 2%)

Sold last year, mainly because Trump administration announced seemingly negative measures toward HMO's in general and specific ones with pharmacy benefits managers. Common theme in the space is that margins are compressing. Overhang will go on for a few more quarters.

TOP PICK

Shares are down because the market fears they will do a tie-up deal with Humana, but CI bowed out. This is good given Human's problems. Managers are excellent, making good deals. EPS grew 13% compounded annual growth rate from 2013-2023. Are buying back shares and pay a dividend.

(Analysts’ price target is $397.05)
PAST TOP PICK
(A Top Pick Jul 27/22, Up 8%)

Exited, and allocated proceeds to UNH, as it's a better performer, larger scale. He also had concerns over customer concentration. Not expensive at 12x forward earnings plus 1.7% yield.

TOP PICK
Healthcare is a unique performer during times of economic deceleration, providing defense and growth. Stable contract with US Defense Department. Share repurchase. 12x forward earnings, value name. 11% growth rate. Reports August 4. Yield is 1.65%. (Analysts’ price target is $295.36)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Feb 11/21, Up 16.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CI has triggered its $245 stop. We recommend covering the balance of the position at this time. Combined with the previous recommendation to cover 50%, this creates a total investment return over 19%
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Feb 11/21, Up 22.5%)Stockchase Research Editor: Michael O'Reilly CI has achieved our objective of $257. To be disciplined we recommend covering 50% of the position and trailing up the stop from $167 to $245. This would all but guarantee a minimum investment return of 19% if triggered.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly CI provides healthcare insurance and services in the US and 30 countries worldwide. They have over 170 million customers. It trades at 15x earnings, compared to the peer average of 23x. Its PEG ratio is 0.95 with earnings growth exceeding 27% this year. Earnings are expected to grow over 10% annually for the next five years. It pays a dividend backed by a payout ratio of only 0.3%. We would buy this with a stop-loss at $167, looking to achieve $257 -- upside exceeding 22%. Yield 1.89% (Analysts’ price target is $257.25)
DON'T BUY
There are better opportunities. It is in a tough space. It is probably not a good market in which to hold stocks that face challenges. All countries are putting pressure on drug prices.
TOP PICK
US health insurance under pressure. Very cheap. Will benefit from next Democratic government when it makes Obamacare better. Retirees who are living off medicare, but want to buy extra insurance, will go to a company like Cigna. Best value without taking on drug pricing or pipeline risk. Huge tailwind in US healthcare space. Yield is 0.02%. (Analysts’ price target is $214.83)
WATCH
Merged with Express Scripts. Whole sector is under pressure because of a recent announcement. Important area which helps keep medical expenses low. He's looking at the sector.
PAST TOP PICK

(A Top Pick Sept 20/16. Up 43%.) He continues to like the US healthcare sector. In the US, if over 65 years of age, you spend 3X as much on healthcare as under the age of 65. This company doesn’t have much exposure to the Affordable Care Act and is well positioned to benefit from those trends.

PAST TOP PICK

(Top Pick Aug 17/16, Up 39.68%) A US based health insurance company. The news was that last year Anthem had made an offer for them, but he thought the takeover would not go through. There is a large break fee for the deal not going through. He thinks going forward they will buy back stock, invest and raise their dividend. It is another well run story.

TOP PICK

A US health insurer provider, one of the largest. There is a pending deal. Aetna (AET-N) (?) wants to buy the company, and it is unlikely that deal gets approved. If the deal doesn’t get approved, the break fee is about $1.5 billion. On top of that, when you look at the cash they can deploy, they are going to have about $10 billion to play with. They can buy back a ton of stock if the deal does not go through. If it does go through, you still get 30% upside. Dividend yield of .03%.

TOP PICK

Health care insurance space, global. A company wanted to buy them and it was rejected by the US government, but they have until next April for the deal to go through. 14 times earnings. They help companies save money. Once the deal does close, or doesn’t, they will have the ability to raise the dividend.

BUY

Do the benefits programs for a lot of small and medium sized businesses and individuals and will benefit from Obama care. It has traded off from fear that businesses would have to now insure all their employees.

Showing 1 to 15 of 15 entries
  • «
  • 1
  • »

Cigna Corp. (CI) Frequently Asked Questions

What is Cigna Corp. stock symbol?

Cigna Corp. is a American stock, trading under the symbol CI (previously CI-N on Stockchase) on the New York Stock Exchange (CI). It is usually referred to as NYSE:CI or CI

Is Cigna Corp. a buy or a sell?

In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on CI (previously CI-N on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Cigna Corp..

Is Cigna Corp. a good investment or a top pick?

Cigna Corp. was recommended as a Top Pick by James Telfser on 2013-06-25. Read the latest stock experts ratings for Cigna Corp..

Why is Cigna Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Cigna Corp..

Is Cigna Corp. worth watching?

Cigna Corp. is followed by 13 investors on Stockchase and is a trending stock that is worth watching.

What is Cigna Corp. stock price?

On 2026-06-15, Cigna Corp. (CI) stock closed at a price of $295.38.